CIK 0001603454 · Non-accelerated filer<br>Smaller reporting company
Celcuity Inc.
Sign in to watch- Ticker
- CELC
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 763-392-0767
- Business address
- 16305 36TH AVENUE N, SUITE 100, MINNEAPOLIS, MN, 55446
- Former names
- Celcuity LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +3,000 | 3,000 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −1,122 | 0 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,122 | 1,122 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −1,301 | 0 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,301 | 1,301 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −1,204 | 0 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,204 | 1,204 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −3,806 | 0 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +3,806 | 3,806 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −15,000 | 0 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −821 | 0 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (right to buy) | +821 | 821 | ||
| 2022-05-17 | Hahne Vicky Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +31,930 | 31,930 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −4,110 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +4,110 | 4,110 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −1,834 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +1,834 | 1,834 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −50,000 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 |
Page 13 of 19 · 365 trades